title: Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective.
abstract: OBJECTIVE
  To examine reasons why rheumatoid arthritis patients discontinued subcutaneous (SQ) anti-tumor necrosis factor (anti-TNF) treatment in the past 12 months, so as to help inform successful, uninterrupted therapy.
  
  
  METHODS
  Data were collected in March and April 2011 using self-reported, internet-based questionnaires. Study inclusion criteria comprised: rheumatoid arthritis diagnosis; discontinuation of SQ anti-TNF medication (adalimumab, certolizumab, etanercept, or golimumab) within the past 12 months; aged ≥18 years; United States residency; and consent to participate. Patients reported primary and other reasons for discontinuation of their most recently discontinued anti-TNF.
  
  
  RESULTS
  Questionnaires from 250 patients were analyzed; 72.8% were female, 80.8% were white, and median age was 51 years. Patients had discontinued etanercept (n=109), adalimumab (n=98), certolizumab (n=24), or golimumab (n=19) within the past 12 months. When prompted about their primary reason for discontinuation, lack of effectiveness (40.8%) was cited most often, followed by injection experience (18.4%). Combining prompted primary and other reasons for discontinuation, 60.8% of patients reported lack of effectiveness, while 40.8% reported injection experience, which included: pain/burning/discomfort after injection (14.4%); pain/burning/discomfort during injection (13.2%); injection reactions such as redness/swelling after injection (12.4%); dislike of self-injection (11.6%); dislike of frequency of injection (10.4%); and fear of injection/needles (6.8%).
  
  
  CONCLUSIONS
  From the patient perspective, there are unmet needs with regard to the effectiveness and injection experience associated with SQ anti-TNF medications, which may lead to discontinuation. Treatment options with a better injection experience may address these needs. These results demonstrate the importance of including the patient perspective when making prescribing decisions or payer access and coverage decisions.
authors: Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
authors: Susan C
authors: SC
authors: Bolge
authors: Health Outcomes Practice, Kantar Health, New York, NY, USA.
authors: Amir
authors: A
authors: Goren
authors: Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, USA.
authors: Neeta
authors: N
authors: Tandon
keywords: anti-TNF; persistence; subcutaneous injection
references: Arthritis Rheum. 2008 Oct 15;59(10):1519-26
references: 18821651
references: Acta Reumatol Port. 2010 Apr-Jun;35(2):192-9
references: 20734542
references: Health Qual Life Outcomes. 2009 Mar 18;7:25
references: 19296831
references: Arthritis Res Ther. 2011 May 25;13 Suppl 1:S5
references: 21624184
references: Arthritis Res Ther. 2011 May 25;13 Suppl 1:S3
references: 21624182
references: Clin Ther. 2013 Dec;35(12):2028-35
references: 24290736
references: J Rheumatol. 2011 Jul;38(7):1273-81
references: 21572150
references: Best Pract Res Clin Rheumatol. 2007 Oct;21(5):907-27
references: 17870035
references: Arthritis Rheum. 2010 Sep;62(9):2569-81
references: 20872595
references: Curr Med Res Opin. 2011 Jan;27(1):71-8
references: 21091097
references: Nat Clin Pract Rheumatol. 2007 Dec;3(12):681
references: 18037928
references: J Rheumatol. 2009 Oct;36(10):2171-7
references: 19723902
references: Eur J Cardiovasc Nurs. 2003 Dec;2(4):323
references: 14667488
references: Arthritis Care Res (Hoboken). 2012 May;64(5):625-39
references: 22473917
references: Pharmacoeconomics. 2004;22(2 Suppl 1):1-12
references: 15157000
references: J Manag Care Pharm. 2009 Nov-Dec;15(9):728-40
references: 19954264
references: Arthritis Res Ther. 2004;6 Suppl 2:S12-8
references: 15228616
references: Arthritis Care Res (Hoboken). 2010 Jun;62(6):857-64
references: 20535797
references: J Rheumatol. 2003 Mar;30(3):443-8
references: 12610798
references: Clin Exp Rheumatol. 2008 Sep-Oct;26(5 Suppl 51):S35-61
references: 19026144